Many think regulatory affairs is about playing safe. It is not. Or at least, the best version of it is not. The stereotype of regulatory affairs is a room full of people slowing everything down, quoting guidelines nobody else has read, adding another review cycle, another document, another justification. In many companies, RA has become synonymous with caution. The department of “no.” The people who turn six weeks into six months because nobody wants to take responsibility fo

Across the pharmaceutical industry, there is a growing tension that most people inside the system recognize, even if it is rarely stated so directly. The cost of developing new medicines keeps increasing, while at the same time governments and payers continue to push prices downward. Each objective makes sense on its own. Everyone wants innovation to continue, and everyone wants medicines to remain affordable. But taken together, these two forces create a structural imbalance

In many pharmaceutical companies, meetings are everywhere. There are project updates, cross-functional discussions, alignment calls, and decision boards. It often feels like a big part of the job is simply attending and talking in meetings. In this environment, there is a quiet skill that is rarely talked about but incredibly valuable: knowing when not to speak. At first, silence can be misunderstood. People may think that if you are quiet, you are not engaged, not prepared,

In industries like pharmaceuticals, medical devices, and biotech, regulatory affairs is often described as the function that “gets products approved” or “keeps companies compliant.” That’s true, but incomplete. When people talk about regulatory affairs leadership , the conversation too often drifts toward authority: who signs off, who enforces procedures, who pushes submissions out the door on time. Let’s be clear: ordering people around, escalating everything, and hiding be